Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 4/20 | 0.56 |
| ▸ | DRD2 | P14416 | 3/20 | 0.56 |
| ▸ | HTR2A | P28223 | 3/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | FAAH | O00519 | 3/20 | 0.54 |
| ▸ | DRD3 | P35462 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4515283 | 0.91 | KDM4E (0.58) | HTR7CYP2D6HTR1ADRD2HTR2A | |
| SCHEMBL3205692 | 0.88 | HTR7 (0.63) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL3187817 | 0.86 | HTR7 (0.63) | HTR7CYP2D6HTR1ADRD2HTR2A | |
| SCHEMBL3198767 | 0.86 | DRD2 (0.52) | HTR7CYP2D6HTR1ADRD2HTR2A | |
| SCHEMBL3230486 | 0.85 | HTR7 (0.59) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL3189302 | 0.84 | KCNH2 (0.51) | HTR7CYP2D6DRD2KCNH2DRD3 | |
| SCHEMBL3187228 | 0.82 | DRD2 (0.67) | HTR7CYP2D6DRD2KCNH2DRD3 | |
| SCHEMBL3187894 | 0.82 | KCNH2 (0.83) | HTR7HTR1ADRD2HTR2AHTR6 | |
| SCHEMBL3194787 | 0.81 | CYP2D6 (0.64) | HTR7CYP2D6HTR1ADRD2HTR2A | |
| Hydrochloric Acid SCHEMBL3196389 | 0.81 | OPRM1 (0.65) | HTR7CYP2D6DRD2KCNH2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | claimed |
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | DRD3, CHRNA3, CHRM3 | HTR7 119/4885CYP2D6 896/4885HTR1A 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.